Trial reportContemporary clinical trials2011
Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.
Trial report in Contemporary clinical trials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease.The Cochrane database of systematic reviews · 2024Pooled it
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease.The Cochrane database of systematic reviews · 2015Pooled it
- Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.Clinical journal of the American Society of Nephrology : CJASN · 2014Trial
- Hypertension in young adults with autosomal dominant polycystic kidney disease: a case for early screening?Clinical kidney journal · 2023Article
- Kynurenines in polycystic kidney disease.Journal of nephrology · 2023Article
- Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease.Scientific reports · 2021Article
- Article
- Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?Pediatric nephrology (Berlin, Germany) · 2019Article
- Article
- Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease.Frontiers in pediatrics · 2017Review
- Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians.Clinical kidney journal · 2015Article
- Autosomal dominant polycystic kidney disease in children.Current opinion in pediatrics · 2015Review
- New treatments for autosomal dominant polycystic kidney disease.British journal of clinical pharmacology · 2013Review
- Angiotensinogen and interleukin 18 in serum and urine of children with kidney cysts.Journal of the renin-angiotensin-aldosterone system : JRAASArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney condition and is associated with important renal and cardiovascular manifestations in childhood. Renal cystic disease can be documented in some cases as early as in utero. Early intervention is critical if the long-term complications of this condition, including end-stage renal disease, are to be ameliorated. Here we describe our ongoing randomized double-blind placebo-controlled phase III clinical trial to assess the effect of pravastatin treatment on renal and cardiovascular disease progression in 107 children and young adults age 8-22 years with ADPKD who are receiving the angiotensin converting enzyme inhibitor lisinopril. Baseline demographic and laboratory data are provided. Results of this study could markedly impact the standard of care for evaluation and treatment of ADPKD in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.